$1.12
+0.03
(+2.75%)▲
4.46%
Downside
Day's Volatility :5.83%
Upside
1.43%
59.6%
Downside
52 Weeks Volatility :71.72%
Upside
30.0%
Period | Gossamer Bio Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 63.17% | 6.5% | 0.0% |
6 Months | 36.23% | 7.1% | 0.0% |
1 Year | -13.49% | 9.8% | 0.0% |
3 Years | -85.58% | 14.2% | -20.2% |
Market Capitalization | 242.1M |
Book Value | $0.12 |
Earnings Per Share (EPS) | -0.85 |
Wall Street Target Price | 6.42 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -43.76% |
Return On Equity TTM | -480.5% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -166.4M |
Diluted Eps TTM | -0.85 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.38 |
EPS Estimate Next Year | -0.74 |
EPS Estimate Current Quarter | -0.19 |
EPS Estimate Next Quarter | -0.11 |
What analysts predicted
Upside of 473.21%
Sell
Neutral
Buy
Gossamer Bio Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Gossamer Bio Inc | 16.04% | 36.23% | -13.49% | -85.58% | -94.85% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Gossamer Bio Inc | NA | NA | NA | -0.38 | -4.8 | -0.44 | NA | 0.12 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Gossamer Bio Inc | Buy | $242.1M | -94.85% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Gossamer Bio Inc
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 75.1%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 272.1%
NEA Management Company, LLC
Artal Group S A
Vanguard Group Inc
EcoR1 Capital, LLC
Octagon Capital Advisors LP
FMR Inc
gossamer bio is a san diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. founded by the former receptos executive team, gossamer bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Organization | Gossamer Bio Inc |
Employees | 135 |
CEO | Mr. Faheem Hasnain |
Industry | Pharmaceuticals: Major |
A Spac I Acquisition Corp
$1.12
+2.75%
Keyarch Acquisition Corp
$1.12
+2.75%
Connexa Sports Technologies Inc
$1.12
+2.75%
Us Value Etf
$1.12
+2.75%
First Wave Biopharma Inc
$1.12
+2.75%
Global X Msci Next Emerging
$1.12
+2.75%
Fat Projects Acquisition Corp
$1.12
+2.75%
Capital Link Global Fintech
$1.12
+2.75%
Applied Uv Inc
$1.12
+2.75%